LAMEA Antibody Drug Conjugates Market Size Report to 2028

LAMEA Antibody Drug Conjugates Market Size, Share & Industry Trends Analysis Report By Application (Breast Cancer, Blood Cancer, Urothelial Cancer & Bladder Cancer, and Others), By Technology, By Country and Growth Forecast, 2022 - 2028

Published Date: May-2022 | Number of Pages: 91 | Format: PDF | Report ID: KBV-18018

Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Antibody Drug Conjugates Market, by Application
1.4.2 LAMEA Antibody Drug Conjugates Market, by Technology
1.4.3 LAMEA Antibody Drug Conjugates Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Acquisition & mergers
3.2.3 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements : 2018, May – 2022, Mar) Leading Players

Chapter 4. LAMEA Antibody Drug Conjugates Market by Application
4.1 LAMEA Breast Cancer Market by Country
4.2 LAMEA Blood Cancer Market by Country
4.3 LAMEA Urothelial Cancer & Bladder Cancer Market by Country
4.4 LAMEA Others Market by Country

Chapter 5. LAMEA Antibody Drug Conjugates Market by Technology
5.1 LAMEA Cleavable Linker Market by Country
5.2 LAMEA Non-Cleavable Linker Market by Country
5.3 LAMEA Others Market by Country

Chapter 6. LAMEA Antibody Drug Conjugates Market by Country
6.1 Brazil Antibody Drug Conjugates Market
6.1.1 Brazil Antibody Drug Conjugates Market by Application
6.1.2 Brazil Antibody Drug Conjugates Market by Technology
6.2 Argentina Antibody Drug Conjugates Market
6.2.1 Argentina Antibody Drug Conjugates Market by Application
6.2.2 Argentina Antibody Drug Conjugates Market by Technology
6.3 UAE Antibody Drug Conjugates Market
6.3.1 UAE Antibody Drug Conjugates Market by Application
6.3.2 UAE Antibody Drug Conjugates Market by Technology
6.4 Saudi Arabia Antibody Drug Conjugates Market
6.4.1 Saudi Arabia Antibody Drug Conjugates Market by Application
6.4.2 Saudi Arabia Antibody Drug Conjugates Market by Technology
6.5 South Africa Antibody Drug Conjugates Market
6.5.1 South Africa Antibody Drug Conjugates Market by Application
6.5.2 South Africa Antibody Drug Conjugates Market by Technology
6.6 Nigeria Antibody Drug Conjugates Market
6.6.1 Nigeria Antibody Drug Conjugates Market by Application
6.6.2 Nigeria Antibody Drug Conjugates Market by Technology
6.7 Rest of LAMEA Antibody Drug Conjugates Market
6.7.1 Rest of LAMEA Antibody Drug Conjugates Market by Application
6.7.2 Rest of LAMEA Antibody Drug Conjugates Market by Technology

Chapter 7. Company Profiles
7.1 Takeda Pharmaceutical Company Limited
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Regional Analysis
7.1.4 Research & Development Expense
7.1.1 Recent strategies and developments:
7.1.1.1 Partnerships, Collaborations, and Agreements:
7.1.1.2 Acquisitions and Mergers:
7.2 F. Hoffmann-La Roche Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
7.2.5.1 Partnerships, Collaborations, and Agreements:
7.3 AstraZeneca PLC
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expenses
7.3.5 Recent strategies and developments:
7.3.5.1 Partnerships, Collaborations, and Agreements:
7.4 GlaxoSmithKline PLC
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Partnerships, Collaborations, and Agreements:
7.4.5.2 Approvals and Trials:
7.5 Pfizer, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional & Segmental Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Partnerships, Collaborations and Agreements:
7.6 Astellas Pharma, Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expense
7.6.5 Recent strategies and developments:
7.6.5.1 Partnerships, Collaborations, and Agreements:
7.6.5.2 Approvals and Trials:
7.7 Gilead Sciences, Inc.
7.7.1 Company overview
7.7.2 Financial Analysis
7.7.3 Research & Development Expenses
7.7.4 Recent strategies and developments:
7.7.4.1 Acquisitions and Mergers:
7.7.4.2 Partnerships, Collaborations and Agreements:
7.8 Seagen, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Research & Development Expenses
7.8.4 Recent strategies and developments:
7.8.4.1 Partnerships, Collaborations, and Agreements:
7.9 ADC Therapeutics SA
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Research & Development Expenses
7.9.4 Recent strategies and developments:
7.9.4.1 Partnerships, Collaborations, and Agreements:
7.9.4.2 Approvals and Trials:
7.10. Daiichi Sankyo Company, Limited
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Research & Development Expense
7.10.4 Recent strategies and developments:
7.10.4.1 Partnerships, Collaborations, and Agreements:

Purchase Report

 1500
 1800
 2520

Special Pricing & Discounts

  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities